Pulsed electromagnetic field treatment for dementia patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study investigates the effects of a pulsed electromagnetic treatment device on patients with mild to moderate Alzheimer's disease and related dementias. Participants will use the device at home for 15 minutes, three times a day, over a period of 120 days. The primary outcome measure will be the Alzheimer's Disease Assessment Scale-Cognitive Subscale, with follow-up assessments conducted for nine months post-treatment. The study aims to evaluate the potential impact of this non-invasive treatment on disease progression.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1\. Age ≥ 50 years 2.2. Patients diagnosed with mild to moderate AD/ADRD including Alzheimer's disease, Lewy body dementia, and Vascular dementia - defined as a global CDR of 0.5 or 1 at baseline.

3\. At least an eighth grade of educational achievement 4. If female, post-menopausal. 5. MMSE score between 16 and 26 (inclusive) 6. Capable of providing consent or having a surrogate (e.g., spouse, family member) capable of providing consent if participant lacks consent capacity 7. Able and willing to comply with the protocol 8. If the participant is receiving a cholinesterase inhibitor and/or memantine, such medication has been prescribed for at least 3 months prior to screening and the dose is stable for at least 60 days prior to screening (that dose needs to be maintained throughout the period of this study) 10. Physical clearance for study participation as evaluated by the clinician

Exclusion Criteria:

1. The patient lacks capacity to consent to study participation and no surrogate is available to provide consent
2. The patient does not have a study partner who would be available for interview
3. History of epileptic seizures or epilepsy
4. Has Frontotemporal Dementia
5. Currently taking medication that lowers the seizure threshold, excluding blood thinners
6. Is currently taking anti-amyloid monoclonal antibodies (past treatment is allowed if termination of treatment occurred at least 3 months prior to the baseline visit).
7. Presence of depression, bipolar disorder, a psychotic disorder, or any other neurological or psychiatric condition (whether now or in the past), which the Investigator finds as interfering with the study
8. Severe agitation that would interfere with study procedures
9. Alcoholism or substance use disorder as defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) within last 5 years (addicted more than one year and or in remission less than 3 years) or severe sleep deprivation
10. Major surgery (defined as any major abdominal, vascular or thoracic surgery requiring general anesthesia and resulting in a period of \>1 week hospitalization) within 4 weeks
11. Head anatomy that interferes with the fit of the treatment device
12. Participation in another clinical trial within the previous 30 days
13. Metal implants in the head, (i.e., cochlear implants, implanted brain stimulators and neurostimulators, aneurysm clips) with the exception of metal implants in mouth
14. Criteria to exclude participants from the blood draw study:

Any condition that may significantly increase risks associated with blood draws

Where it's running

• University of Miami
  Boca Raton, Florida, United States Recruiting

Study contacts

• Study coordinator: Magdalena Tolea, PhD
• Email: mit38@med.miami.edu
• Phone: 561-869-6810

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• What predicts emergency department visits in frail older adults

  This project tests whether a blood marker (plasma pTau181) and signs of cerebrovascular damage can help predict which non-autonomous older adults will need to return to the emergency department within six months.

  Recruiting University of Pisa · Pisa, Pisa · NCT07259499

• Evaluating retinal imaging for neurodegenerative diseases

  This study is testing if special eye scans can help spot early signs of neurodegenerative diseases like Alzheimer's and Parkinson's in people.

  Recruiting Duke University · Durham, North Carolina · NCT03233646

• Identifying differences between Alzheimer's, Lewy Body Dementia, and Parkinson's Disease

  This study is trying to tell apart Alzheimer's, Lewy Body dementia, and Parkinson's Disease by looking at brain scans, tests, and samples from people with these conditions.

  Recruiting Ohio State University · Columbus, Ohio · NCT03019757

• Acoustic Stimulation During Sleep for Alzheimer’s Disease

  Researchers test whether playing gentle sounds during sleep can help people with Alzheimer’s disease see if their thinking improves compared with a sham sound.

  Recruiting Xuanwu Hospital, Beijing · Beijing · NCT07924657

• FAME: A Italian test to recognize famous faces and name them

  This project tests an Italian battery to see how well people with stroke or neurodegenerative diseases recognize famous faces and recall their names, familiarity, and related facts.

  Recruiting at 8 sites Istituti Clinici Scientifici Maugeri SpA · Sciacca, AG and 9 other locations · NCT07911878

• Automated language analysis to help diagnose neurodegenerative diseases

  A multilingual AI-powered language test is being tried to see if speech and language patterns can help differentiate Alzheimer’s, frontotemporal dementia, Lewy body dementia, and Parkinson’s from healthy aging.

  Recruiting Istituti Clinici Scientifici Maugeri SpA · Bari · NCT07906769

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.